# Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

> **NCT00217425** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 46 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT00217425
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-14
- **Primary completion:** 2012-04
- **Final completion:** 2014-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217425, "Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00217425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*